Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $90.1 million.

  • Denali Therapeutics' Total Current Liabilities rose 3.51% to $90.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 3.51%. This contributed to the annual value of $102.2 million for FY2024, which is 31.07% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Total Current Liabilities is $90.1 million, which was down 1.00% from $91.1 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Total Current Liabilities ranged from a high of $391.1 million in Q1 2023 and a low of $51.4 million during Q2 2021.
  • Over the past 3 years, Denali Therapeutics' median Total Current Liabilities value was $87.1 million (recorded in 2024), while the average stood at $111.7 million.
  • As far as peak fluctuations go, Denali Therapeutics' Total Current Liabilities soared by 577.20% in 2022, and later tumbled by 80.26% in 2023.
  • Denali Therapeutics' Total Current Liabilities (Quarterly) stood at $378.2 million in 2021, then dropped by 3.79% to $363.9 million in 2022, then plummeted by 78.57% to $78.0 million in 2023, then soared by 31.07% to $102.2 million in 2024, then increased by 3.51% to $90.1 million in 2025.
  • Its Total Current Liabilities was $90.1 million in Q3 2025, compared to $91.1 million in Q2 2025 and $91.9 million in Q1 2025.